Board of Directors

Mr. Culp is the Chairman and Chief Executive Officer of GE Aerospace. Mr. Culp joined the GE Board of Directors in April 2018 and was appointed Chief Executive Officer of GE in October 2018. In June 2022, he assumed additional duty as Chief Executive Officer of GE Aerospace and became Chairman and Chief Executive Officer of GE Aerospace when it launched as a public company in April 2024. He has also served as the non-executive Chairman of our Board since the Spin-Off. As Chairman and Chief Executive Officer of GE, Mr. Culp led the industrial technology Company’s multi-year financial and operational transformation. Under his leadership, GE further focused the company’s portfolio and simultaneously improved operations across its businesses by implementing and adopting lean with a relentless focus on safety, quality, delivery, and cost—in that order—to better serve customers. These efforts built a strong foundation for the successful creation of three independent, investment-grade public companies GE HealthCare, GE Vernova, and GE Aerospace. Each company is an industry leader with extensive global installed bases and a strong services orientation.

Prior to joining GE, Mr. Culp spent 25 years at Danaher Corporation, including serving as President and Chief Executive Officer from 2001 to 2014. Mr. Culp joined Danaher in 1990 at Veeder-Root, becoming President in 1993. He was appointed Group Executive and Corporate Officer in 1995, with responsibility for Danaher’s Environmental and Electronic Test and Measurement platforms while also serving as President of Fluke and Fluke Networks. He was named Executive Vice President in 1999, Chief Operating Officer in 2000, and President and Chief Executive Officer in 2001. Mr. Culp is a graduate of Washington College and Harvard Business School, and he served as a Senior Lecturer at Harvard Business School from 2015 to 2018. He is a member and former Chairman of the Board of Visitors & Governors of Washington College and also serves as a member of the Board of Trustees of Wake Forest University.

In December 2022, Mr. Arduini was appointed as our President and Chief Executive Officer in connection with the Spin-Off, and he has also served as a member of the Board since the Spin-Off. He served as the President and Chief Executive Officer of GE’s healthcare business from January 2022 until December 2022. Previously, Mr. Arduini was the President and Chief Executive Officer of Integra LifeSciences (“Integra”), a global medical technology company, from January 2012 to December 2021. During his tenure as Integra’s Chief Executive Officer, the Integra portfolio evolved significantly to a faster growing and more profitable company through multiple acquisitions and a sustainable research and development pipeline. Prior to Integra, Mr. Arduini worked at Baxter Healthcare as President of its Medication Delivery division. Before Baxter Healthcare, he spent 15 years at GE’s healthcare business in a variety of leadership roles in the United States and globally, including leading the Computed Tomography and Molecular Imaging business, Healthcare Services and U.S. sales. Mr. Arduini serves on the board of Bristol Myers Squibb and previously served on the board of Integra LifeSciences. Mr. Arduini serves as a Director of the Advanced Medical Technology Association and as a Director and Chair of Funds Development of The National Italian American Foundation.

Dr. Hochman has served as a member of our Board since the Spin-Off. Since January 2025, he has served as Senior Advisor, Healthcare at Bain Capital, LP, a private investment firm, and as Chief Executive Officer Emeritus of Providence, a Catholic not-for-profit health system. From 2016 through December 2024, he served as President and Chief Executive Officer of Providence. He also served on Providence’s board until December 2024.

From 2013 to 2016, Dr. Hochman served as President and Chief Executive Officer of Providence Health & Services, Inc., which merged with St. Joseph Health in 2016 to form Providence St. Joseph Health (now Providence). Earlier, he served as President and Chief Executive Officer of Swedish Medical Center from 2007 to 2012. From 1998 to 2007, he held various leadership roles at Sentara Health System. He is a former Chair of the American Hospital Association and the Catholic Health Association. He previously served on the boards of Diversey Holdings, Ltd. and SonoSite, Inc. He is a Fellow of the American College of Physicians and a Fellow of the American College of Rheumatology.

Dr. Hochman is a director of LeanTaaS and serves as Vice Chair of Boston University’s Board of Trustees and Chair of the Institute for Systems Biology’s Board of Directors. He also serves on the Dean’s Advisory Board of Boston University’s Chobanian & Avedisian School of Medicine and the Foster Advisory Board of the University of Washington’s Foster School of Business. He served as Board Chair of Truveta from 2024 through March 2026.

Ms. Lesjak was appointed to our Board in December 2022 in connection with the Spin-Off. Ms. Lesjak held a broad range of financial leadership roles over a 32-year career at HP Inc. (formerly Hewlett-Packard Company) (“HP”), a multinational information technology company, from which she retired in March 2019. Most recently, from July 2018 until March 2019, she was the interim Chief Operating Officer of HP. From January 2007 to November 2015, Ms. Lesjak was Executive Vice President and Chief Financial Officer of HP, and from November 2015 to July 2018, she was Chief Financial Officer. Ms. Lesjak served as Interim Chief Executive Officer of HP from August 2010 until November 2010. Prior to being named Chief Financial Officer, Ms. Lesjak served as Senior Vice President and Treasurer of HP. Earlier in her career at HP, she managed financial operations for Enterprise Marketing and Solutions and the Software Global Business Unit. Ms. Lesjak serves on the board of GE Aerospace and previously served on the boards of PROS Holdings and SunPower. She also serves on the advisory board for the Haas School of Business, University of California.

Mr. Lobo has served as a member of our Board since March 2026. He has served as Chief Executive Officer of Stryker Corporation (“Stryker”), a global medical technology company, since October 2012 and as Chair of the Stryker Board of Directors since July 2014. From June 2011 to October 2012, he served as President of Stryker’s Orthopedics Group, and from April 2011 to June 2011, as President of Stryker’s Neurotechnology and Spine Group.

Prior to Stryker, Mr. Lobo held various operations leadership roles at Johnson & Johnson, including as President of Ethicon Endo Surgery, and Rhône-Poulenc from 1997 to 2011. Earlier in his career, he held finance roles of increasing responsibility at KPMG, Unilever, and Kraft Canada from 1987 to 1997.

Mr. Lobo served on the board of Parker-Hannifin Corporation from August 2013 through October 2026. He also serves as chair of the board of trustees at Valley Hospital, a director of Advanced Medical Technology Association, and a member of the Business Council.

Ms. Madden has served as a member of our Board since the Spin-Off. Since August 2026, she has served as Senior Advisor at Honeywell Technologies (“Honeywell”), a diversified technology and manufacturing company, and as Senior Advisor at Quantinuum, an integrated quantum computing company. From May 2025 through August 2026, Ms. Madden served as Honeywell’s Senior Vice President, Portfolio Transformation and Senior Advisor. Previously, she served as Honeywell’s Senior Vice President and General Counsel from October 2017 to May 2025 and as Corporate Secretary from January 2018 to September 2019.

Prior to those roles, Ms. Madden served as Honeywell’s Vice President, Corporate Development and Global Head of Mergers & Acquisitions from January 2002 to October 2017. During her tenure, Honeywell completed approximately 100 acquisitions representing approximately $15 billion in revenue and divested approximately 70 businesses representing nearly $9 billion in non-core revenue.

Ms. Madden joined AlliedSignal, Honeywell’s predecessor, in 1996 and subsequently served as Vice President and General Counsel of Performance Materials and Technologies. Earlier in her career, Ms. Madden practiced law at Shearman & Sterling and worked at KPMG.

Ms. Madden served on the board of Quantinuum from June 2021 to May 2026.

Mr. Stromberg has served as a member of our Board since the Spin-Off. Mr. Stromberg served as Interim Chief Investment Officer at Johns Hopkins University from June 2024 to February 2025. From January 2016 through May 2024, Mr. Stromberg was a director of the T. Rowe Price Group, Inc. (“Price Group”), a global investment management firm, and served as the non-executive Chair of the Price Group board from December 2021 through his retirement from the Price Group board in May 2024. Mr. Stromberg served as the Chief Executive Officer of Price Group from January 2016 to December 2021 and was its President from 2016 to February 2021. Prior to that, Mr. Stromberg was Price Group’s Head of Equity from 2009 to 2015 and the Head of U.S. Equity from 2006 to 2009. Earlier in his career at Price Group, he served as a Director of Equity Research and as a portfolio manager. Before joining Price Group in 1987, he was employed by Westinghouse Defense as a systems engineer.  Mr. Stromberg is a director at the Institute for Islamic, Christian, and Jewish Studies, the board of trustees of Johns Hopkins University, and the chair of Johns Hopkins University Whiting School of Engineering Advisory Board.

Ms. Yang has served as a member of our Board since the Spin-Off. She is currently Lecturer in Law at Stanford Law School, where she designed and teaches a course on business leadership in the age of AI. She was the General Manager of Amazon Web Services, Healthcare, a provider of cloud computing platforms and services, between May 2020 and September 2022. Prior to this role, she was at Ascension, where she served as Chief Strategy Officer for Population Health and as Lead Managing Director of Ascension Holdings International. Ms. Yang previously served as a public company senior executive at The Advisory Board Company, Discovery Inc., and AOL Time Warner. Ms. Yang also served as an appointee in two U.S. presidential administrations in the U.S. Department of State and the Federal Communications Commission. Ms. Yang serves on the board of directors of Doximity. She serves as a Board of Stewardship Trustee of CommonSpirit Health, an independent board director of Judi Health, an advisor to Brighton Park Capital, and a Venture Partner at Redesign Health.